
METiS TechBio enters a collaboration with Eli Lilly to develop next-generation, tissue-specific lipid nanoparticle delivery technologies using METiS’s AI-driven lipid discovery platform.
January 27, 2016.
According to R&D leaders participating in a roundtable hosted by the Tufts Center for the Study of Drug Development, drug developers are innovating clinical study volunteer recruitment and retention to significantly improve clinical trial performance and efficiency. Some new approaches include using Big Data to identify and understand patient populations, engaging the “voice of the patient” in trial design, and using new technologies and social media to reach, attract, and keep patients.
Other points made at the Tufts CSDD Executive Forum, summarized in the January
Read the
